BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 25769646)

  • 1. Cross-protection of a new type 2 porcine reproductive and respiratory syndrome virus (PRRSV) modified live vaccine (Fostera PRRS) against heterologous type 1 PRRSV challenge in growing pigs.
    Park C; Choi K; Jeong J; Chae C
    Vet Microbiol; 2015 May; 177(1-2):87-94. PubMed ID: 25769646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of two genetically distant type 2 porcine reproductive and respiratory syndrome virus (PRRSV) modified live vaccines against Vietnamese highly pathogenic PRRSV.
    Do DT; Park C; Choi K; Jeong J; Nguyen TT; Nguyen KD; Vo DT; Chae C
    Vet Microbiol; 2015 Sep; 179(3-4):233-41. PubMed ID: 26149103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Two Commercial Type 1 Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) Modified Live Vaccines against Heterologous Type 1 and Type 2 PRRSV Challenge in Growing Pigs.
    Kim T; Park C; Choi K; Jeong J; Kang I; Park SJ; Chae C
    Clin Vaccine Immunol; 2015 Jun; 22(6):631-40. PubMed ID: 25855554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the efficacy of a new modified live porcine reproductive and respiratory syndrome virus (PRRSV) vaccine (Fostera PRRS) against heterologous PRRSV challenge.
    Park C; Seo HW; Han K; Kang I; Chae C
    Vet Microbiol; 2014 Aug; 172(3-4):432-42. PubMed ID: 24970363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-mediated immune response and protective efficacy of porcine reproductive and respiratory syndrome virus modified-live vaccines against co-challenge with PRRSV-1 and PRRSV-2.
    Madapong A; Saeng-Chuto K; Boonsoongnern A; Tantituvanont A; Nilubol D
    Sci Rep; 2020 Feb; 10(1):1649. PubMed ID: 32015495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A porcine reproductive and respiratory syndrome virus candidate vaccine based on the synthetic attenuated virus engineering approach is attenuated and effective in protecting against homologous virus challenge.
    Evenson D; Gerber PF; Xiao CT; Halbur PG; Wang C; Tian D; Ni YY; Meng XJ; Opriessnig T
    Vaccine; 2016 Nov; 34(46):5546-5553. PubMed ID: 27742217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-protection of a modified-live porcine reproductive and respiratory syndrome virus (PRRSV)-2 vaccine against a heterologous PRRSV-1 challenge in late-term pregnancy gilts.
    Jeong J; Park C; Oh T; Park KH; Yang S; Kang I; Park SJ; Chae C
    Vet Microbiol; 2018 Sep; 223():119-125. PubMed ID: 30173737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Commercial porcine reproductive and respiratory syndrome virus (PRRSV)-2 modified live virus vaccine against heterologous single and dual Korean PRRSV-1 and PRRSV-2 challenge.
    Jeong J; Kim S; Park C; Park KH; Kang I; Park SJ; Chae C
    Vet Rec; 2018 Apr; 182(17):485. PubMed ID: 29472439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of a modified live porcine reproductive and respiratory syndrome virus (PRRSV) vaccine in pigs naturally exposed to a heterologous European (Italian cluster) field strain: Clinical protection and cell-mediated immunity.
    Martelli P; Gozio S; Ferrari L; Rosina S; De Angelis E; Quintavalla C; Bottarelli E; Borghetti P
    Vaccine; 2009 Jun; 27(28):3788-99. PubMed ID: 19442420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Fostera® PRRS modified live virus (MLV) vaccination strategy against a Thai highly pathogenic porcine reproductive and respiratory syndrome virus (HP-PRRSV) infection.
    Charoenchanikran P; Kedkovid R; Sirisereewan C; Woonwong Y; Arunorat J; Sitthichareonchai P; Sopipan N; Jittimanee S; Kesdangsakonwut S; Thanawongnuwech R
    Trop Anim Health Prod; 2016 Oct; 48(7):1351-9. PubMed ID: 27315207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent vaccination of pigs with type 1 and type 2 porcine reproductive and respiratory syndrome virus (PRRSV) protects against type 1 PRRSV but not against type 2 PRRSV on dually challenged pigs.
    Park C; Choi K; Jeong J; Kang I; Park SJ; Chae C
    Res Vet Sci; 2015 Dec; 103():193-200. PubMed ID: 26679817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune response and protective efficacy of intramuscular and intradermal vaccination with porcine reproductive and respiratory syndrome virus 1 (PRRSV-1) modified live vaccine against highly pathogenic PRRSV-2 (HP-PRRSV-2) challenge, either alone or in combination with of PRRSV-1.
    Madapong A; Saeng-Chuto K; Chaikhumwang P; Tantituvanont A; Saardrak K; Pedrazuela Sanz R; Miranda Alvarez J; Nilubol D
    Vet Microbiol; 2020 May; 244():108655. PubMed ID: 32402335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-protective immunity to porcine reproductive and respiratory syndrome virus by intranasal delivery of a live virus vaccine with a potent adjuvant.
    Dwivedi V; Manickam C; Patterson R; Dodson K; Murtaugh M; Torrelles JB; Schlesinger LS; Renukaradhya GJ
    Vaccine; 2011 May; 29(23):4058-66. PubMed ID: 21419162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of an attenuated European subtype 1 porcine reproductive and respiratory syndrome virus (PRRSV) vaccine in pigs upon challenge with the East European subtype 3 PRRSV strain Lena.
    Trus I; Bonckaert C; van der Meulen K; Nauwynck HJ
    Vaccine; 2014 May; 32(25):2995-3003. PubMed ID: 24709589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An interferon inducing porcine reproductive and respiratory syndrome virus vaccine candidate elicits protection against challenge with the heterologous virulent type 2 strain VR-2385 in pigs.
    Fontanella E; Ma Z; Zhang Y; de Castro AM; Shen H; Halbur PG; Opriessnig T
    Vaccine; 2017 Jan; 35(1):125-131. PubMed ID: 27876202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphocyte activation as cytokine gene expression and secretion is related to the porcine reproductive and respiratory syndrome virus (PRRSV) isolate after in vitro homologous and heterologous recall of peripheral blood mononuclear cells (PBMC) from pigs vaccinated and exposed to natural infection.
    Ferrari L; Martelli P; Saleri R; De Angelis E; Cavalli V; Bresaola M; Benetti M; Borghetti P
    Vet Immunol Immunopathol; 2013 Feb; 151(3-4):193-206. PubMed ID: 23228653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A modified-live porcine reproductive and respiratory syndrome virus (PRRSV)-1 vaccine protects late-term pregnancy gilts against heterologous PRRSV-1 but not PRRSV-2 challenge.
    Jeong J; Kang I; Kim S; Park SJ; Park KH; Oh T; Yang S; Chae C
    Transbound Emerg Dis; 2018 Oct; 65(5):1227-1234. PubMed ID: 29536637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of a type 2 PRRSV modified live vaccine (PrimePac™ PRRS) against a Thai HP-PRRSV challenge.
    Sirisereewan C; Woonwong Y; Arunorat J; Kedkovid R; Nedumpun T; Kesdangsakonwut S; Suradhat S; Thanawongnuwech R; Teankum K
    Trop Anim Health Prod; 2018 Oct; 50(7):1509-1518. PubMed ID: 29696456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of simultaneous vaccination with two modified live virus vaccines against porcine reproductive and respiratory syndrome virus types 1 and 2 in pigs.
    Kristensen CS; Kvisgaard LK; Pawlowski M; Holmgaard Carlsen S; Hjulsager CK; Heegaard PMH; Bøtner A; Stadejek T; Haugegaard S; Larsen LE
    Vaccine; 2018 Jan; 36(2):227-236. PubMed ID: 29191738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of commercial type 1 and type 2 PRRSV vaccines against heterologous dual challenge.
    Choi K; Park C; Jeong J; Kang I; Park SJ; Chae C
    Vet Rec; 2016 Mar; 178(12):291. PubMed ID: 26864027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.